Is SYRE or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Generate Biomedicines N/A N/A N/A

Does the media prefer SYRE or GENB?

In the previous week, Generate Biomedicines had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 11 mentions for Generate Biomedicines and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.69 beat Generate Biomedicines' score of 0.35 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALKS or GENB?

In the previous week, Generate Biomedicines had 7 more articles in the media than Alkermes. MarketBeat recorded 11 mentions for Generate Biomedicines and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.48 beat Generate Biomedicines' score of 0.35 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Generate Biomedicines 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Generate Biomedicines N/A N/A N/A

Does the media favor IMVT or GENB?

In the previous week, Immunovant had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 14 mentions for Immunovant and 11 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.35 beat Immunovant's score of 0.27 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Generate Biomedicines 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GENB or RYTM?

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 11 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.35 beat Rhythm Pharmaceuticals' score of 0.24 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GENB or GRAL?

In the previous week, GRAIL had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 13 mentions for GRAIL and 11 mentions for Generate Biomedicines. GRAIL's average media sentiment score of 0.47 beat Generate Biomedicines' score of 0.35 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Generate Biomedicines (GENB) Competitors

$12.77 +0.25 (+2.03%)

As of 11:15 AM Eastern

Compare

GENB vs. SYRE, ALKS, IMVT, RYTM, and GRAL

Should you buy Generate Biomedicines stock or one of its competitors? Generate Biomedicines's main competitors and comparable companies include Spyre Therapeutics (SYRE), Alkermes (ALKS), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), and GRAIL (GRAL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Generate Biomedicines compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Generate Biomedicines (NASDAQ:GENB) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Generate Biomedicines	N/A	N/A	N/A

Spyre Therapeutics presently has a consensus target price of $110.40, suggesting a potential upside of 40.40%. Generate Biomedicines has a consensus target price of $26.40, suggesting a potential upside of 110.86%. Given Generate Biomedicines' higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Spyre Therapeutics has higher earnings, but lower revenue than Generate Biomedicines. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,003.58	-$155.20M	-$1.95	N/A
Generate Biomedicines	$31.89M	50.39	-$203.15M	-$1.59	N/A

In the previous week, Generate Biomedicines had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 11 mentions for Generate Biomedicines and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.69 beat Generate Biomedicines' score of 0.35 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Spyre Therapeutics beats Generate Biomedicines on 8 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Generate Biomedicines (NASDAQ:GENB) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alkermes currently has a consensus target price of $54.47, indicating a potential upside of 39.38%. Generate Biomedicines has a consensus target price of $26.40, indicating a potential upside of 110.86%. Given Generate Biomedicines' higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Generate Biomedicines had 7 more articles in the media than Alkermes. MarketBeat recorded 11 mentions for Generate Biomedicines and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.48 beat Generate Biomedicines' score of 0.35 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.44	$241.66M	$0.38	102.84
Generate Biomedicines	$31.89M	50.39	-$203.15M	-$1.59	N/A

Alkermes has a net margin of 3.96% compared to Generate Biomedicines' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Generate Biomedicines	N/A	N/A	N/A

Summary

Alkermes beats Generate Biomedicines on 12 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Generate Biomedicines (NASDAQ:GENB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Generate Biomedicines has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Generate Biomedicines	$31.89M	50.39	-$203.15M	-$1.59	N/A

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Immunovant had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 14 mentions for Immunovant and 11 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.35 beat Immunovant's score of 0.27 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Generate Biomedicines	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Generate Biomedicines	N/A	N/A	N/A

Immunovant currently has a consensus price target of $44.00, suggesting a potential upside of 57.71%. Generate Biomedicines has a consensus price target of $26.40, suggesting a potential upside of 110.86%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Generate Biomedicines beats Immunovant on 8 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Generate Biomedicines (NASDAQ:GENB) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Generate Biomedicines currently has a consensus target price of $26.40, suggesting a potential upside of 110.86%. Rhythm Pharmaceuticals has a consensus target price of $142.56, suggesting a potential upside of 64.40%. Given Generate Biomedicines' higher probable upside, equities analysts plainly believe Generate Biomedicines is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 11 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.35 beat Rhythm Pharmaceuticals' score of 0.24 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Generate Biomedicines' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Rhythm Pharmaceuticals has higher revenue and earnings than Generate Biomedicines. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	50.39	-$203.15M	-$1.59	N/A
Rhythm Pharmaceuticals	$189.76M	31.31	-$196.54M	-$3.11	N/A

Summary

Generate Biomedicines beats Rhythm Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to GRAIL?

Generate Biomedicines (NASDAQ:GENB) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Generate Biomedicines has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	50.39	-$203.15M	-$1.59	N/A
GRAIL	$147.17M	42.40	-$408.35M	-$9.75	N/A

In the previous week, GRAIL had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 13 mentions for GRAIL and 11 mentions for Generate Biomedicines. GRAIL's average media sentiment score of 0.47 beat Generate Biomedicines' score of 0.35 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines presently has a consensus price target of $26.40, suggesting a potential upside of 110.86%. GRAIL has a consensus price target of $119.80, suggesting a potential downside of 14.24%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe Generate Biomedicines is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Generate Biomedicines has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. Generate Biomedicines' return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
GRAIL	-236.95%	-15.88%	-14.02%

Summary

Generate Biomedicines beats GRAIL on 9 of the 12 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.64B	$3.99B	$7.45B	$12.85B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-8.03	12.82	275.01	25.24
Price / Sales	51.41	1,139.58	569.91	74.84
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	N/A	16.24	10.45	5.96
Net Income	-$203.15M	-$22.69M	$3.50B	$380.84M
7 Day Performance	-8.69%	-4.56%	-2.58%	-3.46%
1 Month Performance	-21.10%	-11.71%	-6.87%	-6.00%
1 Year Performance	N/A	4.51%	1.89%	-5.60%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	2.205 of 5 stars	$12.77 +2.0%	$26.40 +106.7%	N/A	$1.64B	$31.89M	N/A	312	News Coverage
SYRE Spyre Therapeutics	2.6484 of 5 stars	$80.11 -13.6%	$109.71 +37.0%	+274.4%	$7.04B	N/A	N/A	112	Gap Down High Trading Volume
ALKS Alkermes	3.1757 of 5 stars	$41.65 -2.6%	$54.47 +30.8%	+22.4%	$6.99B	$1.48B	109.61	2,050
IMVT Immunovant	2.405 of 5 stars	$32.11 -3.4%	$44.00 +37.0%	+59.5%	$6.63B	N/A	N/A	315
RYTM Rhythm Pharmaceuticals	2.4212 of 5 stars	$90.77 -1.8%	$140.67 +55.0%	-17.6%	$6.22B	$239.92M	N/A	414	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. SYRE, ALKS, IMVT, RYTM, and GRAL

How does Generate Biomedicines compare to Spyre Therapeutics?

Summary

How does Generate Biomedicines compare to Alkermes?

Summary

How does Generate Biomedicines compare to Immunovant?

Summary

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Summary

How does Generate Biomedicines compare to GRAIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. SYRE, ALKS, IMVT, RYTM, and GRAL

How does Generate Biomedicines compare to Spyre Therapeutics?

Is SYRE or GENB more profitable?

Do analysts prefer SYRE or GENB?

Which has stronger earnings and valuation, SYRE or GENB?

Does the media prefer SYRE or GENB?

Do insiders and institutionals hold more shares of SYRE or GENB?

Summary

How does Generate Biomedicines compare to Alkermes?

Do institutionals and insiders hold more shares of ALKS or GENB?

Do analysts rate ALKS or GENB?

Does the media prefer ALKS or GENB?

Which has stronger valuation & earnings, ALKS or GENB?

Is ALKS or GENB more profitable?

Summary

How does Generate Biomedicines compare to Immunovant?

Which has stronger valuation and earnings, IMVT or GENB?

Do insiders and institutionals have more ownership in IMVT or GENB?

Does the media favor IMVT or GENB?

Is IMVT or GENB more profitable?

Do analysts rate IMVT or GENB?

Summary

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Do analysts recommend GENB or RYTM?

Does the media prefer GENB or RYTM?

Is GENB or RYTM more profitable?

Which has higher valuation and earnings, GENB or RYTM?

Summary

How does Generate Biomedicines compare to GRAIL?

Which has stronger earnings & valuation, GENB or GRAL?

Does the media prefer GENB or GRAL?

Do analysts prefer GENB or GRAL?

Is GENB or GRAL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools